Studying Peanut Anaphylaxis

Merz, Beverly

doi:10.1056/nejmp030008

Cited by 6 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A placebo-controlled trial tested the effects of anti-IgE therapy on reactions to peanuts, the dominant cause of food-related anaphylaxis in the US 68. Eighty-four patients were randomized to receive 150, 300, or 450 mg of omalizumab or placebo.…”

Section: Further Therapeutic Activity Of Omalizumab: Off-label Indicamentioning

confidence: 99%

Omalizumab, an anti-immunoglobulin E antibody: state of the art

Incorvaia¹,

Mauro

Russello

et al. 2014

DDDT

View full text Add to dashboard Cite

A large number of trials show that the anti-immunoglobulin (Ig) E antibody omalizumab is very effective in patients with severe allergic asthma. This is acknowledged in consensus documents. The drug also has a good safety profile and a pharmacoeconomic advantage due to a reduction in the number of hospitalizations for asthma attacks. In recent years, some studies have shown that omalizumab is effective also in nonallergic asthma. Effects on the complex signaling mechanisms leading to activation of effector cells and to mediator release may account for this outcome. Indeed, omalizumab has been reported to be effective in a number of IgE-mediated and non-IgE-mediated disorders. Concerning the former, clinical efficacy has been observed in rhinitis, allergic bronchopulmonary aspergillosis, latex allergy, atopic dermatitis, allergic urticaria, and anaphylaxis. In addition, omalizumab has been demonstrated to be able to prevent systemic reactions to allergen immunotherapy, thus enabling completion of treatment in patients who otherwise would have to stop it. Concerning non-IgE-mediated disorders, omalizumab has been reported to be effective in nasal polyposis, autoimmune urticaria, chronic idiopathic urticaria, physical urticaria, idiopathic angioedema, and mastocytosis. Current indications for treatment with omalizumab are confined to severe allergic asthma. Consequently, any other prescription can only be off-label. However, it is reasonable to expect that the use of omalizumab will be approved for particularly important indications, such as anaphylaxis, in the near future.

show abstract

Section: Further Therapeutic Activity Of Omalizumab: Off-label Indicamentioning

confidence: 99%

Omalizumab, an anti-immunoglobulin E antibody: state of the art

Incorvaia¹,

Mauro

Russello

et al. 2014

DDDT

View full text Add to dashboard Cite

show abstract

“…No allergic reactions to the peanut oil were observed. 6,7 . However, it has been suggested that exposure to arachis oil in infancy can lead to an increased risk of developing peanut allergy.…”

Section: Discussionmentioning

confidence: 99%

Naseptin^® and peanut oil: a survey of practitioners' awareness in the UK

2007

View full text Add to dashboard Cite

show abstract

“…Atopic dermatitis is a quite common skin disease in childhood, not uncommon also in allergic adults, in which the elevated and persistent production of IgE antibodies plays an important role (Leung et al 2003). This makes such a disorder a possible target of anti-IgE treatment, but thus far there are scant data on the effects of omalizumab in atopic dermatitis.…”

Section: Other Current and Future Applications Of Omalizumabmentioning

confidence: 99%

“…In US the most frequently responsible food is peanut, which is estimated to cause 50–100 deaths per year. An important randomized controlled study was conducted on 84 patients with allergic reactions to peanut, randomly assigned to receive anti-IgE in doses of 150, 300, or 450 mg, respectively, or placebo (Leung et al 2003). The results showed a significantly higher effectiveness with the 450 mg dose, which increased the threshold of sensitivity to peanut, assessed by oral challenges, from an average of about half a peanut (178 mg) to almost 9 peanuts (2805 mg), an amount far higher than most inadvertent ingestion.…”

Section: Adverse Reactions To Foodsmentioning

confidence: 99%

Current and future applications of the anti-IgE antibody omalizumab

Incorvaia¹,

Mauro²,

Riario-Sforza³

et al. 2008

BTT

View full text Add to dashboard Cite

IgE antibodies are a pivotal factor in pathophysiology of allergic diseases, and the possibility of reducing their level by anti-IgE has long been envisioned. Following several attempts, an effective biologic agent was obtained with the recombinant humanized mono-clonal antibody (rhuMAb)-E25, known as omalizumab. A number of controlled clinical trials demonstrated its efficacy and safety in the treatment of severe allergic asthma uncontrolled by standard drug treatment with maximal recommended doses, and treatment with omalizumab is currently included in international guidelines on asthma management. Other studies reported a clear effectiveness also in allergic rhinitis, but the cost of the anti-IgE treatment suggests its use in patients with rhinitis concomitant with asthma. Other indications to be further investigated are skin disorders such as atopic dermatitis and IgE-mediated urticaria, as well as adverse reactions to foods, with a particularly important role in preventing food-induced anaphylaxis. Finally, there are data indicating the usefulness of omalizumab when used in combination with allergen specific immunotherapy, in terms of reducing the adverse reactions to treatment and increasing the clinical efficacy.

show abstract

Studying Peanut Anaphylaxis

Cited by 6 publications

References 0 publications

Omalizumab, an anti-immunoglobulin E antibody: state of the art

Omalizumab, an anti-immunoglobulin E antibody: state of the art

Naseptin^® and peanut oil: a survey of practitioners' awareness in the UK

Current and future applications of the anti-IgE antibody omalizumab

Contact Info

Product

Resources

About

Studying Peanut Anaphylaxis

Cited by 6 publications

References 0 publications

Omalizumab, an anti-immunoglobulin E antibody: state of the art

Omalizumab, an anti-immunoglobulin E antibody: state of the art

Naseptin® and peanut oil: a survey of practitioners' awareness in the UK

Current and future applications of the anti-IgE antibody omalizumab

Contact Info

Product

Resources

About

Naseptin^® and peanut oil: a survey of practitioners' awareness in the UK